A Phase 3 interventional study of SMT + PE-A 5% and Standard Medical Treatment in Acute-On-Chronic Liver Failure, sponsored by Instituto Grifols, S.A.. Terminated at 30 sites in 9 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Instituto Grifols, S.A. (part of Grifols) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to evaluate the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in acute-on-chronic liver failure (ACLF) subjects. The study will involve approximately 40 study centers in the United States, Canada, and Europe with expertise in the management of subjects with ACLF.
Subjects with ACLF at a high risk of hospital mortality will be enrolled. The study will consist of a Screening Period during which subjects will be randomized (1:1) to receive either standard medical treatment (SMT) + PE-A 5% (treatment group) or SMT only (control group), followed by a Treatment Period, and a Follow-up Period.
The Treatment Period for subjects in the SMT+ PE-A 5% treatment group will be between 7 and 17 days, depending on ACLF evolution.
The Treatment Period for subjects in the SMT control group will be a minimum of 7 days for all subjects and up to 17 days depending on the ACLF evolution. Subjects in this group will receive SMT according to the institution's standards.
The Follow-up Period for subjects in both groups will be 90 days.
Approximately 380 subjects with cirrhosis, ACLF, and high risk of hospital mortality (ACLF-1b, ACLF-2, or ACLF-3a) will be included in this study after obtaining written informed consent. In case of hepatic encephalopathy (HE), written informed consent will be obtained from a relative or a legally authorized representative if the subject is considered incompetent to consent.
Randomization of subjects will be stratified by region (European Union [EU] or North America [NA]) and the 3 ACLF grades (ACLF-1b, ACLF-2, or ACLF-3a). Within each stratum (ie, each unique combination of region and ACLF grade), subjects will be randomized in a 1:1 ratio into 2 treatment groups below:
SMT + PE-A 5% Treatment Group:
PE-A 5% will be performed using 5% albumin (Albutein® 5%) as the main replacement fluid administered intravenously. Fresh frozen plasma (FFP) will be given after each PE-A 5% session to prevent coagulopathy. SMT in addition to PE-A 5% will be administered according to institution standard practice.
The exact number of sessions will be determined by the pattern of response (achieving complete response or no improvement/deterioration of ACLF) to PE-A 5% therapy. IVIGs will be administered to prevent the development of hypogammaglobulinemia and infection.
SMT Control Group:
SMT will be administered according to institution standards practices.
Subjects in both the SMT+ PE-A 5% treatment group and the SMT control group will be followed for 90 days after randomization. During the entire study, the safety of both groups will be monitored by a Data Safety Monitoring Board.
167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.
This study's enrollment of 274 is above the median of 73 across 96 interventional studies indexed under Acute-On-Chronic Liver Failure.
Browse Acute-On-Chronic Liver Failure studies →Instituto Grifols, S.A. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PE-A 5% will be performed using 5% albumin (Albutein 5%) as the main replacement fluid administered intravenously. SMT in addition to PE-A 5% will be administered according to institution standards practice.
Biological: SMT + PE-A 5%
Standard medical treatment (SMT) will be administered according to institution standard practices.
Other: Standard Medical Treatment
Drug page: Albumins humanStudies of Albumins humanAlbumins human pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection. SMT in addition to PE-A 5% according to the institution's standard practice.
Also known as: Albutein 5%
Standard medical treatment according to the institution's standard practice
Also known as: SMT
Time to Death Without a Prior Liver Transplant Through Day 90 After Randomization
Time to 90-day overall survival was to be calculated as \[(date of death) - randomization date\] for those participants who died without having liver transplant on or prior to 90 days. Participants who did not die, or had a liver transplant before death were to have their time to event censored at the earlier of date of last contact, liver transplant date or cut-off date. The percentage of participants with events are presented. The percentage of participants was calculated as \[(participants with an event up to the analysis cut-off day) / (number of participants in the ITT group)\].
Time frame: Up to Day 90
Time to Liver Transplant or Death Through Day 90 After Randomization
Time to 90-day liver transplant free survival was calculated as \[the earlier of the date of liver transplantation or date of death - randomization date for those participants who died or had a liver transplant on or prior to 90 days\]. Participants who neither died nor had a liver transplant, were had their time to event censored at the earlier of date of last contact or cut-off date. The percentage of participants with events are presented. The percentage of participants was calculated as \[(participants with an event up to the analysis cut-off day) / (number of participants in the ITT group)\].
Time frame: Day 1 to Day 90
Time to Death Without a Prior Liver Transplant Through Day 28 After Randomization
Time to 28-day overall survival was calculated as \[date of death - randomization date\] for those participants who died without having liver transplant on or prior to 28 days. Participants who did not die, or had a liver transplant before death were to have their time to event censored at the earlier of date of last contact, liver transplant date or cut-off date. The percentage of participants with events are presented. The percentage of participants was calculated as \[(participants with an event up to the analysis cut-off day) / (number of participants in the ITT group)\].
Time frame: Day 1 to Day 28
A total of 274 participants took part in the study at 29 investigative sites across 8 countries in Europe and the United States from 17 June 2019 to 14 April 2025.
| Milestone | SMT + PE-A 5% | SMT Alone |
|---|---|---|
| Started | 135 | 139 |
| Completed | 36 | 29 |
| Not completed | 99 | 110 |
Time to 90-day overall survival was to be calculated as \[(date of death) - randomization date\] for those participants who died without having liver transplant on or prior to 90 days. Participants who did not die, or had a liver transplant before death were to have their time to event censored at the earlier of date of last contact, liver transplant date or cut-off date. The percentage of participants with events are presented. The percentage of participants was calculated as \[(participants with an event up to the analysis cut-off day) / (number of participants in the ITT group)\].
| Participants | SMT + PE-A 5% | SMT Alone |
|---|---|---|
| Time to Death Without a Prior Liver Transplant Through Day 90 After Randomization | 51 | 69 |
Time to 90-day liver transplant free survival was calculated as \[the earlier of the date of liver transplantation or date of death - randomization date for those participants who died or had a liver transplant on or prior to 90 days\]. Participants who neither died nor had a liver transplant, were had their time to event censored at the earlier of date of last contact or cut-off date. The percentage of participants with events are presented. The percentage of participants was calculated as \[(participants with an event up to the analysis cut-off day) / (number of participants in the ITT group)\].
| Participants | SMT + PE-A 5% | SMT Alone |
|---|---|---|
| Time to Liver Transplant or Death Through Day 90 After Randomization | 87 | 89 |
Time to 28-day overall survival was calculated as \[date of death - randomization date\] for those participants who died without having liver transplant on or prior to 28 days. Participants who did not die, or had a liver transplant before death were to have their time to event censored at the earlier of date of last contact, liver transplant date or cut-off date. The percentage of participants with events are presented. The percentage of participants was calculated as \[(participants with an event up to the analysis cut-off day) / (number of participants in the ITT group)\].
| Participants | SMT + PE-A 5% | SMT Alone |
|---|---|---|
| Time to Death Without a Prior Liver Transplant Through Day 28 After Randomization | 39 | 51 |
Collected over Up to Day 90. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SMT + PE-A 5% | 51/135 (37.8%) | 37/128 (28.9%) | 79/128 (61.7%) |
| SMT Alone | 70/139 (50.4%) | 28/139 (20.1%) | 58/139 (41.7%) |
| Event | SMT + PE-A 5% | SMT Alone |
|---|---|---|
| Shock haemorrhagicVascular disorders | 3/128 | 3/139 |
| Transfusion-related acute lung injuryInjury, poisoning and procedural complications | 3/128 | 1/139 |
| Septic shockInfections and infestations | 2/128 | 3/139 |
| COVID-19Infections and infestations | 1/128 | 3/139 |
| PneumoniaInfections and infestations | 2/128 | 2/139 |
| Escherichia bacteraemiaInfections and infestations | 2/128 | 0/139 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/128 | 1/139 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 2/128 | 0/139 |
| HypotensionVascular disorders | 2/128 | 2/139 |
| Staphylococcal bacteraemiaInfections and infestations | 1/128 | 2/139 |
| Event | SMT + PE-A 5% | SMT Alone |
|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 18/128 | 21/139 |
| AnaemiaBlood and lymphatic system disorders | 18/128 | 11/139 |
| HypotensionVascular disorders | 14/128 | 10/139 |
| Urinary tract infectionInfections and infestations | 13/128 | 6/139 |
| Oedema peripheralGeneral disorders | 12/128 | 5/139 |
| DiarrhoeaGastrointestinal disorders | 11/128 | 6/139 |
| PneumoniaInfections and infestations | 3/128 | 10/139 |
| HypomagnesaemiaMetabolism and nutrition disorders | 8/128 | 8/139 |
| HyperglycaemiaMetabolism and nutrition disorders | 8/128 | 6/139 |
| HypophosphataemiaMetabolism and nutrition disorders | 8/128 | 5/139 |
Intent-to-treat (ITT) population included all participants who were randomized.
| Age, Continuous(years) | SMT + PE-A 5% | SMT Alone | Total |
|---|---|---|---|
| Mean | 50.3 ± 10.92 | 51.1 ± 11.40 | 50.7 ± 11.15 |
| Sex: Female, Male(Participants) | SMT + PE-A 5% | SMT Alone | Total |
|---|---|---|---|
| Female | 46 | 42 | 88 |
| Male | 89 | 97 | 186 |
| Race (NIH/OMB)(Participants) | SMT + PE-A 5% | SMT Alone | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 4 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 12 | 19 |
| White | 121 | 118 | 239 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 5 | 11 |
| Ethnicity (NIH/OMB)(Participants) | SMT + PE-A 5% | SMT Alone | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 17 | 31 |
| Not Hispanic or Latino | 121 | 122 | 243 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | SMT + PE-A 5% | SMT Alone | Total |
|---|---|---|---|
| United States | 49 | 48 | 97 |
| Austria | 7 | 7 | 14 |
| Belgium | 17 | 17 | 34 |
| France | 6 | 5 | 11 |
| Germany | 17 | 14 | 31 |
| Italy | 15 | 16 | 31 |
| Portugal | 3 | 2 | 5 |
| Spain | 16 | 21 | 37 |
| United Kingdom | 5 | 9 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Apr 2025, 69 months.
Results were first posted in Jun 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumins human
Acute-On-Chronic Liver Failure →